Goodwin Procter Advises Epoch Biodesign on $18.3M Series A Funding.
Epoch Biodesign, a UK-based innovator in biorecycling, has successfully raised $18.3 million in its Series A funding round, with Goodwin Procter advising the startup. The funding will help the company scale its groundbreaking work on plastic-eating enzymes.
Funding Details and Investors
The funding round was led by Extantia Capital, a climate-focused investment firm. It also attracted participation from several prominent investors including Day One Ventures, Happiness Capital, Kibo Invest, and Lowercarbon Capital. A key highlight of the round was a strategic investment by Inditex, the Spanish multinational fashion giant behind Zara, through its venture arm, Mundi Ventures.
Epoch Biodesign’s Mission: Tackling Plastic Waste
Founded in 2019 by Jacob Nathan, Epoch Biodesign began as a high school science project aimed at using enzymes to break down plastic waste. Today, the company is a dynamic team of over 30 professionals working across chemistry, biology, and software engineering to scale up its innovative biorecycling technology.
With this funding, Epoch Biodesign will expand its operations by transferring its plastic-eating enzyme production from the laboratory to its first production facility, slated to open later this year.
Epoch Biodesign was advised by the London and Cambridge Technology team at Goodwin Procter, with Adam Thatcher and Duy Le leading the legal team throughout the fundraising process. Their guidance helped the startup navigate the complex legal landscape of raising capital in the growing sustainability and climate-tech sectors.
Epoch Biodesign is a cutting-edge biotech company focused on solving climate challenges by leveraging nature’s machinery. They specialize in developing enzymes that address previously impossible applications, particularly in plastic waste degradation.
Founded in 2019 by Jacob Nathan, Epoch combines AI, chemistry, biology, and engineering to pioneer the future of biodesign. Their diverse, multidisciplinary team of over 30 scientists and engineers is dedicated to creating impactful, sustainable solutions.
The company is poised to scale its plastic-eating enzyme production with recent funding to support its innovative biorecycling processes. Epoch’s work stands as a testament to groundbreaking science and bold environmental action.
With the infusion of capital, Epoch Biodesign is poised to accelerate its efforts in biorecycling. The company aims to scale the production of its plastic-eating enzymes, offering a new and innovative approach to tackling the global plastic waste crisis. The strategic backing from investors like Inditex and Extantia Capital positions Epoch Biodesign for significant growth and impact in the climate-tech industry.
Goodwin Procter LLP is a leading global law firm known for its expertise in complex legal matters across various industries, including technology, life sciences, private equity, and real estate. Founded in 1912, the firm offers a wide range of legal services, including corporate law, mergers and acquisitions, litigation, intellectual property, and regulatory affairs. With offices in major cities around the world, Goodwin Procter is committed to delivering high-quality legal solutions to clients, from startups to multinational corporations. The firm is recognized for its innovation, client service, and dedication to fostering diversity and inclusion within the legal profession.